Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

Peter R. Carroll, MD
Published: Tuesday, Feb 10, 2015



Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.
 
As more biomarker-based tests become prevalent, options for identifying and treatment prostate cancer are going to expand. Prostate-specific antigen (PSA) screenings aren’t going away, says Carroll, but other types of testing should become standard in the future to reduce the amount of unnecessary biopsies.
 
Once a PSA has identified a high-risk patient, follow-up serum tests or imaging tests should be conduced to determine which patients will benefit from a biopsy. 


Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.
 
As more biomarker-based tests become prevalent, options for identifying and treatment prostate cancer are going to expand. Prostate-specific antigen (PSA) screenings aren’t going away, says Carroll, but other types of testing should become standard in the future to reduce the amount of unnecessary biopsies.
 
Once a PSA has identified a high-risk patient, follow-up serum tests or imaging tests should be conduced to determine which patients will benefit from a biopsy. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x